From the publishers of JADPRO

Cardio-Oncology Updates

.

KINASE INHIBITORS

Home Kinase Inhibitors News & Literature Highlights

Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib

This review article explores the cardiovascular risks and mechanisms related to tyrosine kinase inhibitor therapy among patients with chronic myeloid leukemia, with a spotlight on ponatinib, including recent reported discoveries and future strategies for minimizing the CML-TKI–associated cardiotoxicities.

International Journal of Cardiology

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

View More

Videos

Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study

Kinase Inhibitors Managing Nilotinib-Associated Cardiotoxicity in CML: A Case Study

Kinase Inhibitors Kinase Inhibitors and Cardiotoxicity: The Pharmacist Perpsective

General Cardio-Oncology Welcome Message from the Program Chair

View More